Abstract 3123
Background
The use of ICTs has become widespread in recent years. There is little information available in Turkey about the level of usage of ICTs for and by cancer patients.
Methods
This descriptive study was conducted to determine the level of ICTs use and patterns of preferences among cancer patients in Ankara, Turkey. The survey was started on March 2019 and the data collection process is continuing. The sample size was determined as 334 and 173 patients were reached. In data collection, a questionnaire including 38 questions about patient demographics, use of cell phones, the interest of patients in using ICTs to receive information about cancer, and the interest of patients in using ICTs to communicate with health care providers about cancer. The study was approved by university research and ethics committees and informed consent were obtained from patients.
Results
The mean age of the participants was 60.19±12.60 (range 27-89 years), 68.2% were female, 45.7% were primary school graduate. Mean duration of diagnosis was 24.12± 28.56 (range 1-120) months, 26% were breast cancer, 21.4 % had metastasis. Of the total, 78.6% of participants reported that they had access to the internet. The ICTs used at least once a week was found to be respectively WhatsApp (63.5%), Facebook (60.7%), instagram (34.1%), youtube (32.3%) and short message service (SMS) text messaging (31.7%). With regard to the preferences on how patients would like to use ICTs to receive information about diseases, Internet (63.0%), SMS (21.3%) and WhatsApp (19.6%) were widely reported as interesting communication channels. Participants 61.8% rely on information obtained through ICTs. Internet (36.4%), SMS (17.3%) followed by WhatsApp (15.0%, 26/173) were reported as the preferred ICTs through which patients would like to ask health providers about diseases. Adjusted regression analysis showed that patients aged between 45-64 years were more likely to be interested in receiving information through SMS than the oldest group.
Conclusions
In this study, we have determined that SMS text messaging presented the highest rate of interest for receiving information and communicating with health providers, followed by WhatsApp.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3524 - Cabazitaxel For Octogenarian Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC).
Presenter: Paolo Tralongo
Session: Poster Display session 3
Resources:
Abstract
5637 - External Validation of a Prognostic Score in First-Line Metastastic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: David Lorente
Session: Poster Display session 3
Resources:
Abstract
3228 - Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: results from the Dutch CAPRI-registry
Presenter: Jessica Notohardjo
Session: Poster Display session 3
Resources:
Abstract
4695 - Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion>5%: a propensity score matching analysis from SEER database
Presenter: Junru Chen
Session: Poster Display session 3
Resources:
Abstract
4438 - Multi-institutional evaluation of therapeutic management for oligometastatic cancer prostate recurrence with choline-PET/CT
Presenter: Morgane Guibert-broudic
Session: Poster Display session 3
Resources:
Abstract
4574 - Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): a network meta-analysis of randomized controlled trials (RCT)
Presenter: Amelia Altavilla
Session: Poster Display session 3
Resources:
Abstract
3816 - Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): results from the Dutch CAPRI registry
Presenter: Malou Kuppen
Session: Poster Display session 3
Resources:
Abstract
5180 - A phase 2a study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
1067 - Adding ADT to PSMA-PET/CT-guided SBRT for oligometastatic prostate cancer improves distant progression-free survival
Presenter: Carole Mercier
Session: Poster Display session 3
Resources:
Abstract
5529 - Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA
Presenter: Robert Tauber
Session: Poster Display session 3
Resources:
Abstract